Zofran ODT
Zofran ODT
Generic Name
Zofran ODT
Mechanism
- Competitive antagonist at peripheral and central 5‑HT3 receptors
- *Peripheral*: blocks receptors on vagal afferent nerves in the gut, preventing emetic signaling.
- *Central*: antagonizes receptors in the chemoreceptor trigger zone (CTZ) of the medulla oblongata, inhibiting nausea/vomiting reflex.
- Inhibition of the serotonin surge that occurs after cytotoxic therapy, surgery, or motion stimulus.
- Results in a rapid reduction of nausea and vomiting without central nervous system depression.
Pharmacokinetics
- Absorption: Rapid, with peak plasma concentrations (Tmax) at ~2–3 h for tablets; ODT may reach peak slightly earlier due to faster dissolution.
- Bioavailability: 65–70 % after oral administration; unaffected by food.
- Distribution: Volume of distribution ≈ 10 L; highly protein‑bound (~90 %).
- Metabolism: Primarily hepatic via CYP1A2 and CYP3A4; minor role of CYP2D6.
- Elimination: Renally excreted; 30–40 % unchanged, 60–70 % as metabolites.
- Half‑life: ~3.5 h (range 3–4 h).
- Drug interactions: Moderately potent CYP1A2 inhibitor—use with caution when co‑administered with substrates (e.g., clozapine, carbamazepine).
Indications
- Chemotherapy‑induced nausea and vomiting (CINV):
- *Highly emetogenic* regimens (e.g., cisplatin).
- *Moderately emetogenic* regimens (e.g., anthracycline‑taxane).
- Post‑operative nausea and vomiting (PONV): When combined with dexamethasone or NK1 antagonists.
- Radiation‑induced nausea in pelvic or head‑and‑neck fields.
- Acute migraine‑related nausea (off‑label).
- Motion sickness (limited evidence, off‑label).
Contraindications
- Contraindications:
- Known hypersensitivity to ondansetron or any excipients.
- Pre‑existing congenital long‑QT syndrome.
- Warnings:
- QT prolongation / torsades de pointes – risk elevated with concurrent use of other QT‑prolonging drugs (e.g., haloperidol, cisapride, cisapride, citalopram).
- Serotonin syndrome – caution when combined with agents that increase serotonin (e.g., SSRIs, SNRIs, MAOIs).
- Seizure risk – rare in patients with pre‑existing seizure disorder when overdosed.
Dosing
| Population | Dosage | Administration | Notes |
| Adults | 4 mg (single dose) | ODT orally disintegrating (sprinkle on tongue) | Re‑dose 4 mg after 1–4 h if vomiting recurs. Max 8 mg/day. |
| 8 mg (single dose) | For highly emetogenic chemotherapy | Use 4 mg twice daily may be considered for severe cases. | |
| Pediatrics | 0.1 mg/kg (max 4 mg) | ODT or oral solution | Weight‑based dosing; monitor for efficacy. |
| Geriatric | Use standard adult dose; adjust for renal/hepatic impairment | Same | Review renal function (CrCl) to avoid accumulation. |
• Timing: Administer within 30 min before chemotherapy or 60 min before surgery.
• Oral Solution: May be used for patients who cannot swallow tablets.
Adverse Effects
Common (≤10 %)
• Headache
• Dizziness
• Constipation or diarrhea
• Blurred vision
• Mild rash or pruritus
Serious (≤1 %)
• QT prolongation → torsades de pointes, ventricular arrhythmia
• Serotonin syndrome (hypercervical rigidity, tremor, hyperthermia) when combined with serotonergic drugs
• Seizures in predisposed individuals
• Neurotoxicity: rare cases of encephalopathy or neuropathy
• Allergic reactions: urticaria, angioedema, anaphylaxis
• Hypotension: rarely symptomatic bradycardia or low blood pressure
Monitoring
- Baseline EKG if QT prolongation risk factors present.
- Serial EKGs when using multiple QT‑prolonging agents or high‑risk patients.
- Serotonergic drug combinations: monitor for signs of serotonin syndrome.
- Renal/hepatic function: adjust dosing if necessary.
- Vital signs: watch for hypotension in septic or hypovolemic patients.
Clinical Pearls
- Best Timing is Key: Give Zofran ODT 30 min prior to chemotherapy or anesthesia for optimal protection.
- OTD Advantage: Ideal when patients are nauseated enough to avoid swallowing tablets; dissolves in 80 %.
- QT Risk in Polypharmacy: In patients on citalopram, haloperidol, or ondansetron concurrently, consider a lower dose (4 mg) or add a short‑acting antipsychotic for breakthrough nausea.
- Renal Impairment: Ondansetron clearance is modestly reduced; in CrCl < 30 mL/min, monitor for accumulation but no formal dose reduction is required.
- Pediatric Dosing Simplified: Weight‑based 0.1 mg/kg, with a 4 mg ceiling; 0.2 mg/kg if high‑risk regimen.
- Serotonin Syndrome Alert: If patient on MAO‑I or SSRI, discontinue ondansetron or switch to a different antiemetic.
- Storage: Keep at room temperature, protect from moisture; shelf life 36 months after manufacture.
--
• Zofran ODT remains a cornerstone antiemetic for chemotherapeutic, peri‑operative, and radiation‑induced nausea. Its rapid action, ease of use, and well‑characterized safety profile make it a go‑to option for clinicians seeking reliable prophylaxis of nausea and vomiting.